Table 8: Sensitivity analyses.

ScenarioBase case value in ItalyBase case value in SpainBase case value in SwedenEffect

Duration of partial remission following first-line treatment with doxorubicin/ifosfamide ranges from 6.1 to 9.2 months7.7 months7.7 months7.7 monthsDoxorubicin/ifosfamide remains a dominant treatment
Duration of stable disease following first-line treatment with doxorubicin/ifosfamide ranges from 5.1 to 7.7 months6.4 months6.4 months6.4 monthsDoxorubicin/ifosfamide remains a dominant treatment
Duration of partial remission following first-line treatment with trabectedin ranges from 7.0 to 10.6 months8.8 months8.8 months8.8 monthsDoxorubicin/ifosfamide remains a dominant treatment
Duration of stable disease following first-line treatment with trabectedin ranges from 6.0 to 9.0 months7.5 months7.5 months7.5 monthsDoxorubicin/ifosfamide remains a dominant treatment
Probability of being in stable disease after first-line doxorubicin/ifosfamide ranges from 0.3 to 0.50.380.380.38Doxorubicin/ifosfamide remains a dominant treatment
Probability of being in stable disease after first-line trabectedin ranges from 0.1 to 0.20.140.140.14Doxorubicin/ifosfamide remains a dominant treatment
Probability of being in stable disease after second-line trabectedin ranges from 0.35 to 0.500.440.440.44Doxorubicin/ifosfamide remains a dominant treatment
Probability of switching to trabectedin after first-line doxorubicin/ifosfamide ranges from 80% below to 20% above the base case value0.500.260.30Doxorubicin/ifosfamide remains a dominant treatment except in Italy where its costeffectiveness ranges from being dominant to €21,500 per QALY, breaking even at a probability of 0.55
Length of hospital stay for doxorubicin/ifosfamide infusion ranges from 1 to 5 days3 days4 days3 daysDoxorubicin/ifosfamide remains a dominant treatment except in Italy where its costeffectiveness ranges from being dominant to €16,400 per QALY, breaking even at 4 days
Unit cost of doxorubicin ranges from 80% below to 20% above the base case value€119.50€4.11€59.79Doxorubicin/ifosfamide remains a dominant treatment
Unit cost of ifosfamide ranges from 80% below to 20% above the base case value€30.71€19.71€65.65Doxorubicin/ifosfamide remains a dominant treatment
Unit cost of trabectedin ranges from 80% below to 20% above the base case value€2,970.10€2,049.91€1,913.29Doxorubicin/ifosfamide remains a dominant treatment except in Italy where its costeffectiveness ranges from €11,200 per QALY to being dominant, breaking even at €2,570
Cost of managing adverse events ranges from 80% below to 20% above the base case valuesDoxorubicin/ifosfamide remains a dominant treatment
Cost of pre- and postchemotherapy medications ranges from 80% below to 20% above the base case valuesDoxorubicin/ifosfamide remains a dominant treatment
Cost of palliative care ranges from 80% below to 20% above the base case valuesDoxorubicin/ifosfamide remains a dominant treatment
Utility for progressive disease ranges from 0.24 to 0.360.300.300.30Doxorubicin/ifosfamide remains a dominant treatment
Utility for stable disease ranges from 0.34 to 0.520.430.430.43Doxorubicin/ifosfamide remains a dominant treatment
Difference in QALYs gained following the start of treatment with doxorubicin/ifosfamide and trabectedin ranges from 80% below and 20% above the base case value0.070.040.02Doxorubicin/ifosfamide remains a dominant treatment